Articles

Concurrent Treatment of Advanced Melanoma with Ipilimumab and Nivolumab

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Ipilimumab for Initial Treatment of Metastatic Uveal Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Nivolumab Combined with Ipilimumab in Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Gefitinib Plus Carboplatin/Pemetrexed as First-Line Therapy of EGFR+ NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

First-Line Nivolumab Monotherapy in Advanced NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Results from the ARCHER 1009 Study: Dacomitinib Versus Erlotinib for Second-/Third-Line Therapy of Locally Advanced or Metastatic NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Results from PROFILE 1014: First-Line Crizotinib Versus Pemetrexed-Platinum in ALK+ NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Erlotinib Plus Bevacizumab as First-Line Treatment for EGFR+, Advanced NSCLC

ASCO 2014 – Lung Cancer, ASCO

Conference Correspondent

Adjuvant Ipilimumab for Patients with High-Risk Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

First Trial Assessing Nivolumab in Platinum-Resistant Ovarian Cancer

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Page 227 of 329